

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:)	Docket No.:	4354-110
)		
Applicants:)	Conf. No.:	4322
Application No.:)	Art Unit:	1614
Date Filed:)	Examiner:	Phyllis G. Spivack
Title:)	Customer No.:	23448
RIFALAZIL COMPOSITIONS AND THERAPEUTIC REGIMENS)		

CERTIFICATE OF EFS FILING

I hereby certify that this document is being filed via EFS in the United States Patent and
Trademark Office on **January 5, 2010**.
/david bradin/

**RESPONSE TO DECEMBER 31, 2009 INTERVIEW SUMMARY IN
U.S. PATENT APPLICATION NO. 10/668,792**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

On December 31, 2009, Examiner Phyllis G. Spivack issued an Interview Summary setting out the particulars of a December 29, 2009 teleconference regarding matters in the above-identified U.S. patent application.

The undersigned attorney confirms the acceptability of the Interview Summary as provided by the Examiner, and notes that in accordance with the Examiner's statements, a Request for Examination (RCE) was filed in the present application on December 31, 2009.

Respectfully submitted,

/david bradin/
David Bradin
Reg. No. 37,783
Attorney for Applicant(s)

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Phone: (919) 419-9350
Fax: (919) 419-9354
Attorney File No.: 4354-110

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284